Related Experiment Video
Updated: Feb 3, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
CPX-351: From preclinical studies to future directions
A Sperotto1, G Ciotti2, M Basso3
1UOSD Terapie Cellulari - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy; UOC Oncoematolgia - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy.
Abstract:
For decades, the standard induction treatment for patients with acute myeloid leukemia (AML) has been the 7 + 3 regimen (cytarabine plus daunorubicin). The US-Food and Drug Administration (FDA) approved, in August 2017, the use CPX-351 for adults with newly diagnosed secondary AML. CPX-351 (also known as VYXEOS) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin in a synergistic 5:1 M ratio, and CombiPlex was utilized, a combination drug technology platform. In this review, we analyze the path from preclinical studies to drug registration. Recent research highlights intestinal and heart toxicity of the drug, as well as current and potential future uses for CPX-351.
More Related Videos
06:16An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research
Published on: February 2, 2022
10:193D Kinematic Gait Analysis for Preclinical Studies in Rodents
Published on: August 3, 2019
Related Concept Videos
Preclinical Development: Overview
Directing Effect of Substituents: meta-Directing Groups
Directing Effect of Substituents: ortho–para-Directing Groups
Directional Terms
Directional Relays
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...